Receive our newsletter – data, insights and analysis delivered to you
July 5, 2009

Eisai Begins Trials on Paediatric Leukaemia Drug Dacogen

Japanese company Eisai has announced that its US subsidiary Eisai Medical Research will begin trials of Dacogen for injection in paediatric patients with acute myelogenous leukaemia (AML) in the US. The clinical trial will be conducted in accordance with a Written Request issued by the US

By cms admin

Japanese company Eisai has announced that its US subsidiary Eisai Medical Research will begin trials of Dacogen for injection in paediatric patients with acute myelogenous leukaemia (AML) in the US.

The clinical trial will be conducted in accordance with a Written Request issued by the US Food and Drug Administration (FDA).

If the FDA determines that the data from the clinical trial appropriately meet requirements set out in the Written Request, six-month paediatric exclusivity will be granted for Dacogen, extending its patent to November 2013.

Dacogen has already been approved by the FDA and is indicated in the US for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS.

AML is a life-threatening disease and the most common form of acute leukaemia. It is estimated that the US incidence of AML in children age 0–14 is 6.9 per one million people.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU